Contact Information

Available for logged-in reporters only

Newswise The Institute for Research in Immunology and Cancer (IRIC) at the Universit de Montral (UdeM), in collaboration with the Maisonneuve-Rosemont Hospitals Quebec Leukemia Cell Bank, recently achieved a significant breakthrough thanks to the laboratory growth of leukemic stem cells, which will speed up the development of new cancer drugs.

In a recent study published in Nature Methods, the scientists involved describe how they succeeded in identifying two new chemical compounds that allow to maintain leukemic stem cells in culture when these are grown outside the body.

This important advance opens the way to the identification of new cancer drugs to fight acute myeloid leukemia, one of the most aggressive forms of blood cancer.

The ability to grow leukemic stem cells in culture is a major breakthrough. The next step is to study the molecular mechanisms that regulate the survival and proliferation of leukemic cells as well as the resistance to cancer drugs.

This study is the work of the Leucgne research group. This group is co-directed by Dr. Guy Sauvageau, chief executive officer and principal investigator at IRIC as well as professor in the Department of Medicine at the UdeM; by Dr. Jose Hbert, director of the Quebec Leukemia Cell Bank, hematologist at Maisonneuve-Rosemont Hospital and professor in the Department of Medicine at the UdeM; and by Sbastien Lemieux, principal investigator at IRIC. The first author of the study is Caroline Pabst, a postdoctoral fellow at IRIC and associate of the Leucgne research group.

This research breakthrough demonstrates the advantage of working in a multidisciplinary team like the Leucgne research group, stated Drs. Sauvageau and Hbert. Access to cells of leukemia patients and to IRICs state-of-the-art facilities are also key factors in pursuing ground-breaking research.

Background to the study Stem cells located in the bone marrow are responsible for the production of blood cells. Unfortunately, deregulation of those cells often produces disastrous consequences when one of them develops mutations that transform it into a malignant cell called leukemic. The result is an abnormal proliferation of blood cells and the development of leukemia. Leukemic stem cells are also one of the likely causes of patient relapse because they are especially resistant to cancer treatments.

The major obstacle before this discovery was growing stem cells and keeping them intact in vitro, because they quickly lost their cancer stem cell character. As a result, it was very difficult to effectively study the multiplication of cells that cause leukemia.

Originally posted here:
Major Breakthrough in Developing New Cancer Drugs: Capturing Leukemic Stem Cells

Comments are closed.